Think of Verquvo as a “Niche” Med for Heart Failure
December 2023
Reps will tout vericiguat (Verquvo) as a new once-daily add-on for worsening heart failure with reduced ejection fraction (HFrEF).
Vericiguat is a “soluble guanylate cyclase stimulator.” It’s like riociguat (Adempas)...both relax blood vessels through the nitric oxide pathway.
But vericiguat is used in heart failure with reduced ejection fraction while riociguat is used in pulmonary hypertension.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive